ArticleAnnals of clinical microbiology and antimicrobials2018
An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study.
Article in Annals of clinical microbiology and antimicrobials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 214 citations in OpenAlex.
- Virulence factors and antimicrobial resistance of uropathogenic Escherichia coli (UPEC) isolated from urinary tract infections: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2020Pooled it
- Genomic diversity and high-risk lineages in clinical Escherichia coli from Mexico.Archives of microbiology · 2026Article
- Antibiofilm Potential and Mechanisms ofMicroorganisms · 2026Article
- Genomic analysis of jumbo coliphage fEgEco12.Archives of virology · 2026Article
- Can phage-antibiotic combinations overcome uropathogenic Escherichia coli regrowth? evidence from in vitro and in vivo models.Virology journal · 2026Article
- Extended spectrum beta-lactamase producing Escherichia coli encoding aminoglycoside and fluoroquinolone resistant genes in urinary tract infection patients in a tertiary hospital in Nigeria.BMC infectious diseases · 2025Article
- Clonal Diversity of Extraintestinal PathogenicAntibiotics (Basel, Switzerland) · 2025Article
- The role of uropathogenicJournal of medicine and life · 2025Review
- Antimicrobial Resistance and Virulence Determinants ofAnimals : an open access journal from MDPI · 2025Article
- Intestinal and Extraintestinal Pathotypes ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Canine urothelial cell model to study intracellular bacterial community development by uropathogenic Escherichia coli.PloS one · 2025Article
- Genomic analysis and characterization of lytic bacteriophages that target antimicrobial resistantHeliyon · 2024Article
- High Carriage ofTropical life sciences research · 2024Article
- UropathogenicCurrent issues in molecular biology · 2024Article
- Comprehensive Assessment of Multidrug-Resistant and Extraintestinal PathogenicMicroorganisms · 2024Article
- Correlation between antimicrobial resistance, biofilm formation, and virulence determinants in uropathogenic Escherichia coli from Egyptian hospital.Annals of clinical microbiology and antimicrobials · 2024Article
- Clinical and epidemiological characteristics of multi-drug resistantJournal of medicine and life · 2024Article
- Characterization of ES10 lytic bacteriophage isolated from hospital waste against multidrug-resistant uropathogenicFrontiers in microbiology · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUropathogenic Escherichia coli (UPEC) are one of the main bacteria causing urinary tract infections (UTIs). The rates of UPEC with high resistance towards antibiotics and multidrug-resistant bacteria have increased dramatically in recent years and could difficult the treatment.
methodsThe aim of the study was to determine multidrug-resistant bacteria, antibiotic resistance profile, virulence traits, and genetic background of 110 E. coli isolated from community (79 isolates) and hospital-acquired (31 isolates) urinary tract infections. The plasmid-mediated quinolone resistance genes presence was also investigated. A subset of 18 isolates with a quinolone-resistance phenotype was examined for common virulence genes encoded in diarrheagenic and extra-intestinal pathogenic E. coli by a specific E. coli microarray.
resultsFemale children were the group most affected by UTIs, which were mainly community-acquired. Resistance to trimethoprim-sulfamethoxazole, ampicillin, and ampicillin-sulbactam was most prevalent. A frequent occurrence of resistance toward ciprofloxacin (47.3%), levofloxacin (43.6%) and cephalosporins (27.6%) was observed. In addition, 63% of the strains were multidrug-resistant (MDR). Almost all the fluoroquinolone (FQ)-resistant strains showed MDR-phenotype. Isolates from male patients were associated to FQ-resistant and MDR-phenotype. Moreover, hospital-acquired infections were correlated to third generation cephalosporin and nitrofurantoin resistance and the presence of kpsMTII gene. Overall, fimH (71.8%) and fyuA (68.2%), had the highest prevalence as virulence genes among isolates. However, the profile of virulence genes displayed a great diversity, which included the presence of genes related to diarrheagenic E. coli. Out of 110 isolates, 25 isolates (22.7%) were positive to qnrA, 23 (20.9%) to qnrB, 7 (6.4%) to qnrS1, 7 (6.4%) to aac(6')lb-cr, 5 (4.5%) to qnrD, and 1 (0.9%) to qnrC genes. A total of 12.7% of the isolates harbored bla
conclusionsUrinary tract infection due to E. coli may be difficult to treat empirically due to high resistance to commonly used antibiotics. Continuous surveillance of multidrug resistant organisms and patterns of drug resistance are needed in order to prevent treatment failure and reduce selective pressure. These findings may help choosing more suitable treatments of UTI patients in this region of Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.